person · Reporting owner
Vazzano Joseph Walter
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Chief Financial Officer | July 21, 2026 | July 22, 2026 |
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Chief Financial Officer | December 17, 2021 | December 20, 2021 |
| Allarity Therapeutics, Inc.ALLR · Entity 7594 | Director | January 22, 2025 | January 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date July 21, 2026 · Filed July 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 492,079 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Sale · Disposed 1,478 · Balance 492,079 F1: Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards.
AVENUE THERAPEUTICS, INC.
Report date December 17, 2021 · Filed December 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 165,757 |
Reported balance
After 2021-12-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-12-17 · Grant · Acquired 100,505 · Balance 165,757 F1: This restricted stock unit award (RSU) vests on March 15, 2022. Each RSU is equivalent to one share of the Company's common stock. F2: Includes 100,505 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: This restricted stock unit award (RSU) vests on March 15, 2022. Each RSU is equivalent to one share of the Company's common stock.
F2: Includes 100,505 RSUs.
Allarity Therapeutics, Inc.
Report date January 22, 2025 · Filed January 25, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2035-01-22 | Direct | 25,000 |
Reported balance
After 2025-01-22 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-01-22 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2026 Filed Jul 22, 2026 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 1,478 | $6.53 | $9,651.34 |
DisclosureSEC source: 0001493152-26-034246 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492,079 F1 · kind: Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards. Read SEC document |
| July 09, 2026 Filed Jul 9, 2026 23:24 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 24,880 | $6.96 | $173,256.86 |
DisclosureSEC source: 0001493152-26-032746 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,557 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 00:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 25,646 | $5.39 | $138,288.36 |
DisclosureSEC source: 0001493152-26-028022 · ownership.xml · nonDerivative · entry 3 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 518,437 F4 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 21, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.30 to $5.42 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 00:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 13,421 | $5.30 | $71,187.67 |
DisclosureSEC source: 0001493152-26-028022 · ownership.xml · nonDerivative · entry 2 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 544,083 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 00:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 10,271 | $5.43 | $55,766.39 |
DisclosureSEC source: 0001493152-26-028022 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 557,504 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 16, 2026 Filed Mar 16, 2026 20:29 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 785 | $4.76 | $3,736.60 |
DisclosureSEC source: 0001493152-26-010276 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 567,775 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 01:34 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 18,666 | $5.33 | $99,506.58 |
DisclosureSEC source: 0001493152-26-003284 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 568,560 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 21:31 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 133,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-002889 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 587,226 F1 · shares: The restricted stock will vest one-third on each of January 20, 2027, January 20, 2028, and January 20, 2029. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 9,035 | $5.39 | $48,730.27 |
DisclosureSEC source: 0001493152-25-016542 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,631 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.35 to $5.46 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 15, 2025 Filed Aug 15, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 15,000 | $7.36 | $110,358.00 |
DisclosureSEC source: 0001493152-25-012099 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,666 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.20 to $7.48 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 22, 2025 Filed Jul 22, 2025 20:15 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 1,502 | $6.64 | $9,974.63 |
DisclosureSEC source: 0001641172-25-020575 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477,666 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · balance_after: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.63 to $6.65 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 25,411 | $5.86 | $148,799.19 |
DisclosureSEC source: 0001641172-25-018604 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,168 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.78 to $5.92 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 06, 2025 Filed Jun 6, 2025 22:04 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 17,795 | $6.76 | $120,294.20 |
DisclosureSEC source: 0001641172-25-014178 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 491,246 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.76 to $6.79 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:31 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-014321 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 504,579 F1 · shares: The restricted stock will vest one-third on each of June 5, 2026, June 5, 2027, and June 5, 2028. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 685 | $5.29 | $3,623.65 |
DisclosureSEC source: 0001493152-25-010591 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,041 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| January 22, 2025 Filed Jan 25, 2025 01:10 UTC Amendment | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-25-001854 · rdgdoc.xml · derivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-01-22 F1 · derivative.exercise_date: The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:13 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-25-001796 · rdgdoc.xml · derivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-01-22 F1 · derivative.exercise_date: The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 23:56 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 144,509 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-003464 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,726 F1 · shares: The restricted stock will vest one-third on each of January 21, 2026, January 21, 2027 and January 21, 2028. Read SEC document |
| September 28, 2024 Filed Sep 30, 2024 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 6,388 | $5.89 | $37,625.32 |
DisclosureSEC source: 0001493152-24-038799 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,217 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| July 21, 2024 Filed Jul 22, 2024 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 1,055 | $5.11 | $5,391.05 |
DisclosureSEC source: 0001493152-24-028697 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,605 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 155,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026648 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 372,660 F1 · shares: The restricted stock will vest one-third on each of July 8, 2025, July 8, 2026 and July 8, 2027. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:33 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 16,408 | $4.52 | $74,164.16 |
DisclosureSEC source: 0001493152-24-023125 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,460 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 12:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon stock | 5,608 | $3.14 | $17,609.12 |
DisclosureSEC source: 0001493152-24-016062 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,868 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.13 to $3.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 15, 2024 21:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 703 | $8.14 | $5,722.42 |
DisclosureSEC source: 0001493152-24-010132 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,260 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 29, 2023 Filed Sep 29, 2023 21:17 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 6,230 | $3.93 | $24,483.90 |
DisclosureSEC source: 0001493152-23-034904 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,963 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 13:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon stock | 2,986 | $3.82 | $11,406.52 |
DisclosureSEC source: 0001493152-23-033142 · ownership.xml · nonDerivative · entry 2 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,179 Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 13:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon stock | 14 | $3.70 | $51.80 |
DisclosureSEC source: 0001493152-23-033142 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,193 Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 00:10 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 1,187 | $3.73 | $4,427.51 |
DisclosureSEC source: 0001493152-23-025515 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,179 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:15 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 141,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-020416 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,366 F1 · shares: The restricted stock will vest one-third on each of June 5, 2024, June 5, 2025 and June 5, 2026. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Tax withholdingCommon stock | 792 | $2.60 | $2,059.20 |
DisclosureSEC source: 0001493152-23-008076 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,458 F1 · kind: Represents shares of restricted stock surrendered to satisfy the reporting person's tax withholding obligation upon vesting of restricted stock. The deemed disposition of the withheld shares is exempt pursuant to Rule 16b-3(e). Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 14:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon stock | 2,500 | $4.00 | $10,000.00 |
DisclosureSEC source: 0001493152-22-033018 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,250 Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 72,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027277 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,750 F1 · shares: The restricted stock will vest 25% on each of September 28, 2023, September 28, 2024, September 28, 2025 and September 28, 2026. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 22:17 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-020281 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: The restricted stock will vest 25% on each of July 21, 2023, July 21, 2024, July 21, 2025 and July 21, 2026. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:08 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-006976 · ownership.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · shares: The restricted stock will vest 25% on each of March 14, 2023, March 14, 2024, March 14, 2025 and March 14, 2026. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 22:07 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 100,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151771 · tm2135922-3_4seq1.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,757 F1 · shares: This restricted stock unit award (RSU) vests on March 15, 2022. Each RSU is equivalent to one share of the Company's common stock. F2 · balance_after: Includes 100,505 RSUs. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 20:03 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | SaleCommon Stock | 7,160 | $1.62 | $11,599.20 |
DisclosureSEC source: 0001104659-21-115916 · tm2127741-1_4seq1.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,252 F1 · shares: On September 15, 2021, a total of 7,160 shares were sold by the Company at a weighted average sales price of $1.62 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 20:15 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | SaleCommon Stock | 3,840 | $12.13 | $46,579.20 |
DisclosureSEC source: 0001104659-20-097594 · tm2029210d1_4.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,412 F1 · shares: On August 20, 2020, a total of 3,840 shares were sold by the Company at a weighted average sales price of $12.13 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| March 10, 2020 Filed Mar 10, 2020 20:42 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 1,889 | $7.94 | $14,998.66 |
DisclosureSEC source: 0001104659-20-031410 · tm2012321d1_form4.xml · nonDerivative · entry 3 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,252 Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:42 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 100 | $7.97 | $797.00 |
DisclosureSEC source: 0001104659-20-031410 · tm2012321d1_form4.xml · nonDerivative · entry 2 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,363 Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:42 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 1,400 | $7.99 | $11,186.00 |
DisclosureSEC source: 0001104659-20-031410 · tm2012321d1_form4.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,263 Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 21:55 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 1,200 | $9.09 | $10,908.00 |
DisclosureSEC source: 0001104659-20-024815 · tm2010943d12_4.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,863 Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 21:32 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantRestricted Stock Units · Derivative | 22,727 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-020237 · tm208004-2_form4.xml · derivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,505 Underlying: Common Stock · 22,727 shares Expires 2025-02-12 F1 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Avenue Therapeutics, Inc. The RSUs vest upon the earliest to occur of the following: (i) Grantee's death or disability; (ii) a change in control of Avenue Therapeutics, Inc.; or (iii) the Second Stage Closing with InvaGen. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 20:19 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | SaleCommon Stock | 2,375 | $5.56 | $13,205.00 |
DisclosureSEC source: 0001144204-19-039191 · tv527358_4.xml · nonDerivative · entry 2 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,663 F2 · price: On August 9, 2019, a total of 2,375 shares were sold by the Company at a weighted average sales price of $5.56 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 20:19 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | SaleCommon Stock | 2,313 | $5.62 | $12,999.06 |
DisclosureSEC source: 0001144204-19-039191 · tv527358_4.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,038 F1 · price: On August 8, 2019, a total of 2,313 shares were sold by the Company at a weighted average sales price of $5.62 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:42 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantRestricted Stock Units · Derivative | 27,778 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-029900 · tv523099_form4.xml · derivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,778 Underlying: Common Stock · 27,778 shares Expires 2024-06-03 F1 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Avenue Therapeutics, Inc. The RSUs vest upon the earliest to occur of the following: (i) Grantee's death or disability; (ii) a change in control of Avenue Therapeutics, Inc.; or (iii) the Second Stage Closing with InvaGen. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 01:50 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-042965 · tv500471_form4.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · VP Finance & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,351 F1 · shares: The 30,000 shares of restricted common stock will vest as follows: one-fourth on August 7, 2019, one-fourth on August 7, 2020, one-fourth on August 7, 2021, and one-fourth on August 7, 2022. Read SEC document |
| June 28, 2018 Filed Jun 28, 2018 17:09 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 1,351 | $3.66 | $4,944.66 |
DisclosureSEC source: 0001144204-18-036289 · tv497535_form4.xml · nonDerivative · entry 1 Vazzano Joseph Walter · CIK 0001715291 · VP Finance & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,351 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.